Navigation Links
Martek Announces Second Quarter 2009 Financial Results

-- Record revenues of $92.4 million

-- Record non-infant formula nutritional sales of $9.8 million

-- Record pre-tax income of $17.1 million

-- Earnings per share of $0.33, an increase of 20% over last year's second quarter

-- Operating cash flow of $17 million (Year-to-date operating cash flow of $26 million)

-- Full fiscal year 2009 earnings guidance of $1.20 - $1.25 per share, pre-tax earnings growth of 10% to 15% over fiscal 2008

-- Memory study results to be released in July 2009

COLUMBIA, Md., June 3 /PRNewswire-FirstCall/ -- Martek Biosciences Corporation (Nasdaq: MATK) today announced its financial results for the second quarter of fiscal 2009. Revenues for the second quarter were $92.4 million, up 2% from $90.7 million in the second quarter of fiscal 2008. Net income was $11.0 million, or $0.33 per diluted share, for the second quarter of fiscal 2009, a 20% increase compared with $9.2 million, or $0.28 per diluted share, in last year's second quarter.

Commenting on the quarter, Chief Executive Officer Steve Dubin said, "The continued execution of our business plan allowed Martek to generate record revenues and profits in the second quarter. These results were achieved despite the challenges of a struggling global economy. We continue to be encouraged by recent infant formula sales data which indicates that end consumer demand for infant formula is stable despite the weak global economic environment. As such, while infant formula related revenue in the second half of our fiscal 2009 will be impacted by some inventory de-stocking, Martek is still expecting strong 2009 earnings as a result of growth in our non-infant formula business and controlling our expenses during this period. I believe our growing non-infant formula business coupled with an expected resumption in growth in our infant formula business in 2010 will lay a solid foundation for 2010."

Revenue Summary

Product sales in the second quarter of fiscal 2009 increased to $88.2 million from $87.9 million in the second quarter of fiscal 2008. Second quarter revenue growth was driven by sales of life'sDHA(TM) to non-infant formula nutritional markets which grew to a record level of $9.8 million, up from $8.3 million in the prior year's second quarter. The 18% increase in non-infant formula nutritional products was led by significantly higher sales to the pregnancy and nursing market.

The following is a breakdown of product sales by market for the second quarter and year-to-date periods (in thousands):

                                Three months ended      Six months ended
                                  April 30,                April 30,
                                ------------------      ----------------

                                2009    2008    %         2009    2008    %
                                               incr                      incr
                                              (decr)                    (decr)

    Infant formula market    $77,383  $78,390  (1%)   $151,974  $148,668   2%
    Food and beverage market   2,979    3,172  (6%)      5,597     5,267   6%
    Pregnancy and nursing,
     nutritional supplements
     and animal feeds          6,801    5,113   33%     12,465    10,405  20%
    Non-nutritional products     989    1,200  (18%)     2,138     2,144   0%
                              ------   ------  ----    -------   -------  --
       Total product sales   $88,152  $87,875  0.3%   $172,174  $166,484   3%
                              ======   ======  ====    =======   =======  ==

In addition, contract manufacturing sales in the second quarter totaled $4.3 million, compared with $2.9 million a year ago. This increase was primarily due to a change in the timing of orders from one existing customer. While the Company expects to continue reducing the scope of its contract manufacturing activities, Martek will, at times, provide such services to both existing and new customers if reasonable profit margins are expected and there is no impact to the Company's higher margin nutritional oils business.

Gross Margin and Operating Expenses

Overall gross margin for the second quarter of fiscal 2009 was 42.3%, an increase over the 41.2% gross margin realized in the second quarter of fiscal 2008. The improvement resulted largely from ARA cost reductions and increased capacity utilization at Martek's manufacturing facilities.

Research and development expenses in the second quarter of fiscal 2009 were $7.2 million, an increase of 5% over the corresponding quarter of last year. Research and development as a percentage of revenue increased to 7.7% from 7.5% in the prior year's second quarter. The increase relates primarily to development work focusing on offerings for new markets and broadening the array of foods and beverages in which the Company's life'sDHA(TM) can be incorporated. The Company continues to expect quarter-to-quarter fluctuations in research and development expenses mainly due to the timing of outside services, including third-party clinical trial services.

During the second quarter of fiscal 2009, selling, general and administrative expenses ("SG&A") were $12.9 million, or 13.9% of revenue, a decrease from $14.2 million or 15.7% of revenue in last year's second quarter. The Company continues to closely manage its SG&A spending levels. Martek expects that for fiscal 2009, SG&A will be lower than fiscal 2008 levels on both a percentage of revenue and absolute dollar basis reflecting the cost management measures employed by the Company to address economic challenges.

Financial Position

For the six months ended April 30, 2009, the Company generated $25.6 million of cash from operating activities, with the second quarter providing $17.0 million of this total. As of the end of the second quarter, Martek had $117.9 million in cash and cash equivalents, a minimal amount of debt and the entire balance of its long-term revolving credit facility ($135 million) available for future borrowing.

Significant Recent Events

  • Non-Infant Formula Product Launches - Several non-infant formula nutritional products with Martek's life'sDHA(TM) were launched by Martek's customers, including Walmart Spring Valley DHA dietary supplements and The Coca Cola Company's Minute Maid Blueberry Pom single serve beverage, an extension of Minute Maid's current Pomegranate Blueberry juice with life'sDHA(TM).

  • Multi-Year Sole-Source Infant Formula Supply Agreements - Martek entered into multi-year, sole-source infant formula supply agreements with Rice Field Corporation ("Rice Field") and Lactalis Nutrition Sante ("Lactalis"). Under the Rice Field agreement, Martek will supply its DHA and ARA blend for all infant formula products manufactured by Rice Field under the Prodigy brand. Rice Field will also be using Martek's life'sDHA(TM) and life'sARA(TM) in its growing-up milks and will be using life'sDHA(TM) in its products for pregnant and nursing women, all of which will be sold under the Prodigy brand in China. Under the Lactalis agreement, Martek will supply its life'sARA(TM) for use in infant formula and growing-up milks produced by Lactalis and sold in France and Algeria.

  • Multi-Year Exclusive Food and Beverage Supply Agreement - Martek entered into a multi-year supply agreement with Ragasa, one of Mexico's largest providers of raw and refined oil products and maker of Mexico's leading consumer cooking oil brand, Nutrioli, under which Ragasa has agreed to purchase all of its DHA omega-3 needs from Martek. Ragasa plans to launch a product featuring life'sDHA(TM) in 2009 and will display the life'sDHA(TM) logo on the product packaging and in all related promotional materials.

  • Arrangement for the Production of Influenza Drug Precursor - Consistent with the services provided by Martek in 2006, Martek has been re-engaged to manufacture shikimic acid, the starting material used to produce an anti-viral drug for the treatment of influenza. Sales for such services are expected to approximate $4.5 million, with one-half of this total anticipated to occur in Martek's fourth quarter of fiscal 2009 and the remainder anticipated to occur during the first half of fiscal 2010.

  • New Scientific Data Published on DHA - A summary document for the International Society for the Study of Fatty Acids and Lipids published in Prostaglandins, Leukotrienes and Essential Fatty Acids (February 2009) discussed obtaining adequate DHA intake in light of current western diets. They concluded that with no other changes in diet, improvement of blood DHA status can be achieved with dietary supplements of preformed DHA (such as Martek's life'sDHA(TM)), but not with supplementation of ALA, EPA, or other precursors.

Memory Study Results to be Released

Martek's Memory Improvement With Docosahexaenoic Acid Study (MIDAS) clinical trial studying the effects of life'sDHA(TM) supplementation in improving cognitive functions (i.e. - working memory, memory retention and attention) in healthy subjects with age-related cognitive decline has concluded. Results of this study will be the subject of an oral presentation at the International Conference on Alzheimer's Disease to be held July 11 - 16, 2009 in Vienna, Austria.

Financial Guidance

Based on recent retail sales data, Martek estimates that overall end consumer demand for infant formula in the United States as well as internationally is stable despite the weak global economy. Nonetheless, we believe that de-stocking of infant formula inventory is occurring at both the retail level as well as the manufacturer level (our customers). As a result of this inventory de-stocking, Martek's infant formula revenue is expected to be negatively impacted during the Company's third and fourth fiscal quarters by a combined total of $10 million to $15 million.

Martek expects total revenues for the third quarter of fiscal 2009 to be between $77 million and $85 million with third quarter infant formula revenue projected to be between $63 million and $70 million and third quarter non-infant formula nutritional revenue projected to be between $8.5 million and $10.5 million. Third quarter gross margin is expected to be approximately 43%. Net income for the third quarter is projected to be between $7.7 million and $9.3 million, and diluted earnings per share are projected to be between $0.23 and $0.28.

For the full fiscal year 2009, Martek expects total revenues to be between $350 million and $355 million. Net income for the full fiscal year 2009 is projected to be between $40 million and $42 million, and diluted earnings per share are projected to be between $1.20 and $1.25, a pre-tax earnings increase of between 10% and 15% over fiscal 2008.

The Company anticipates that infant formula revenue will grow in fiscal 2010 as a result of continued strong end consumer demand for infant formula products containing DHA and ARA.

Investor Conference Call Webcast

Martek will host a conference call and Webcast for investors to review its second quarter results and fiscal 2009 outlook at 4:45 p.m. Eastern Time on Wednesday, June 3, 2009. Access to the live audio Webcast is available through Martek's website at The webcast will be available for replay through the close of business on July 3, 2009.


Sections of this release contain forward-looking statements concerning, among other things: (1) Martek's expectations regarding future revenue growth in and customer demand from the infant formula, pregnancy and nursing, nutritional supplements, animal feeds and food and beverage markets; (2) its expectations and beliefs regarding the impact of customer de-stocking on revenues in the third and fourth quarters of fiscal 2009; (3) its expectations regarding revenue, gross margin, operating expenses and income for the third quarter of and full fiscal year 2009; and (4) its expectations regarding launches by customers of products containing Martek's life'sDHA(TM) and Martek's contract manufacturing business. Furthermore, Martek's operating results are subject to quarter-to-quarter fluctuations, some of which may be significant. The forward-looking statements noted above are based upon numerous assumptions which Martek cannot control and involve risks and uncertainties that could cause actual results to differ. These statements should be understood in light of the risk factors and cautionary statements set forth herein and in the Company's filings with the Securities and Exchange Commission, including, but not limited to, Part I, Item 1A of the Company's Form 10-K for the fiscal year ended October 31, 2008 and other filed reports on Form 10-K, Form 10-Q and Form 8-K.

About Martek

Martek Biosciences Corporation (Nasdaq: MATK) is a leader in the innovation and development of omega-3 DHA products that promote health and wellness through every stage of life. The Company produces life'sDHA(TM), a vegetarian source of the omega-3 fatty acid DHA (docosahexaenoic acid), for use in foods, infant formula and supplements, and life'sARA(TM) (arachidonic acid), an omega-6 fatty acid, for use in infant formula. For more information on Martek Biosciences, visit

                             MARTEK BIOSCIENCES CORPORATION
                     Summary Consolidated Financial Information
                (Unaudited) - $ in thousands, except per share data

    Unaudited Condensed Consolidated Statements of Income Data

                                        Three months ended  Six months ended
                                            April 30,            April 30,
                                        ------------------  ----------------
                                          2009      2008    2009     2008
                                          ----      ----    -----    ----

       Product sales                   $88,152   $87,875  $172,174  $166,484
       Contract manufacturing sales      4,259     2,851    7,600      7,123
                                        ------    ------   -------   -------
       Total revenues                   92,411    90,726   179,774   173,607
                                        ------    ------   -------   -------
     Cost of revenues:
       Cost of product sales            49,299    50,579    96,208    95,676
       Cost of contract manufacturing
        sales                            4,017     2,764     7,426     6,452
                                        ------    ------   -------   -------
       Total cost of revenues           53,316    53,343   103,634   102,128
                                        ------    ------   -------   -------
           Gross margin                 39,095    37,383    76,140    71,479
                                        ------    ------   -------   -------
     Operating expenses:
       Research and development          7,157     6,819    13,906    12,800
         Selling, general and
         administrative                 12,875    14,234    25,972    27,215
        Amortization of intangible
         assets                          1,595     1,877     3,376     3,556
        Other operating expenses           569        96       722       249
                                         ------   ------    ------   -------
        Total operating expenses         22,196   23,026    43,976    43,820
                                         ------   ------    ------   -------
     Income from operations              16,899   14,357    32,164    27,659
     Interest income (expense) and
      other, net                            186      309       346       526
                                         ------    -----    ------    ------
     Income before income tax
      provision                          17,085   14,666    32,510    28,185
     Income tax provision                 6,068    5,464    11,887    10,314
                                         ------   ------    ------    ------
     Net income                         $11,017   $9,202   $20,623   $17,871
                                         ======   ======    ======    ======
     Basic earnings per share            $ 0.33   $ 0.28     $0.62     $0.54
                                         ======   ======    ======    ======
     Diluted earnings per share          $ 0.33   $ 0.28     $0.62     $0.54
                                         ======   ======    ======    ======
     Shares used in computing basic
      earnings per share                 33,190   32,916    33,170    32,830
     Shares used in computing diluted
      earnings per share                 33,310   33,231    33,349    33,151

    Unaudited Condensed Consolidated Balance Sheets Data

                                                    April 30,  October 31,
                                                        2009         2008
                                                    --------    ---------

        Cash and cash equivalents                   $117,944     $102,495
        Accounts receivable, net                      52,898       40,438
        Inventories, net                             109,603       99,553
        Other current assets                           3,905        4,866
        Property, plant and equipment, net           259,747      265,900
        Deferred tax asset                            25,819       38,356
        Long-term investments                         11,615       11,336
        Goodwill and other, net                       84,029       83,037
                                                     -------      -------
     Total assets                                   $665,560     $645,981
                                                     =======      =======

     Liabilities and stockholders' equity:
        Current liabilities                          $43,420      $47,342
        Non-current liabilities                        9,301       10,056
        Stockholders' equity                         612,839      588,583
                                                     -------      -------
     Total liabilities and stockholders' equity     $665,560     $645,981
                                                     =======      =======

    Unaudited Condensed Consolidated Cash Flow Data

                                                         Six months ended
                                                             April 30,
                                                          2009       2008
                                                          ----       ----

     Operating activities:
        Net income                                    $20,623     $17,871
        Non-cash items                                 27,671      24,611
        Changes in operating assets and liabilities,
         net                                          (22,663)     (3,726)
                                                       ------      ------
        Net cash provided by operating activities      25,631      38,756
                                                       ------      ------

     Investing activities:
        Purchase of investments and marketable
         securities, net                                    -     (10,850)
        Expenditures for property, plant and
         equipment                                     (5,263)     (3,576)
        Capitalization of intangible assets            (4,435)     (2,165)
                                                        -----      ------
      Net cash used in investing activities            (9,698)    (16,591)
                                                        -----      ------

     Financing activities:
        Repayments of notes payable and other
         long-term obligations, net                       (59)       (426)
       (Payments) proceeds from equity transactions,
         net                                             (425)      5,944
                                                          ---       -----
       Net cash (used in) provided by financing
         activities                                      (484)      5,518
                                                          ---       -----

        Net change in cash and cash equivalents        15,449      27,683
        Cash and cash equivalents,
         beginning of period                          102,495      16,973
                                                      -------      ------

        Cash and cash equivalents, end of period     $117,944     $44,656
                                                      =======      ======

    Kyle Stults
    Investor Relations
    (410) 740-0081

SOURCE Martek Biosciences Corporation
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Study Demonstrates Marteks Algal DHA Oil Improves Blood Triglyceride Lipid Levels
2. Martek Announces Third Quarter 2007 Financial Results
3. Martek Announces Addition of lifesDHA(TM) to Entire Bellybar(TM) Line of Nutrition Bars
4. Martek Signs Multi-Year Infant Formula License and Supply Agreement with Alter Farmacia
5. Marteks lifesDHA(TM) Featured in New Beech-Nut(R) DHA Plus Baby Food and Cereals
6. Martek Wins German DHA Patent Infringement Actions Against Lonza and One of Nutrinovas Customers in Suits Relating to DHA Product Marketed for Use in Functional Foods and Dietary Supplements
7. Martek Signs Exclusive Worldwide Distributorship Agreement with Novus International
8. Marteks lifesDHA(TM) Featured in Dalco Foods Wellness Line Meat Products
9. Martek Announces Settlement of Class Action Lawsuit
10. Pocket Rocket Juice from Australias Boost Juice Features 700 mg of Marteks lifesDHA(TM)
11. Summary Notice of Proposed Settlement and Settlement Hearing in Re Martek Biosciences Corp., Securities Litigation
Post Your Comments:
(Date:10/13/2017)... Abilene, Texas (PRWEB) , ... October 13, 2017 , ... ... publication this week that explains one of the most popular and least understood books ... seems like cryptic and puzzling descriptions that have baffled scholars for centuries. Many have ...
(Date:10/13/2017)... ... 13, 2017 , ... “The Journey: From the Mountains to the Mission Field”: ... souls in the Philippines. “The Journey: From the Mountains to the Mission Field” is ... Bible. She has taught all ages and currently teaches a class of ladies at ...
(Date:10/12/2017)... CA (PRWEB) , ... October 12, 2017 , ... ... Cheng, are now treating sleep apnea using cutting-edge Oventus O2Vent technology. ... a serious sleep disorder characterized by frequent cessation in breathing. Oral appliances can ...
(Date:10/12/2017)... ... October 12, 2017 , ... IsoComforter, Inc. ( ... introduction of an innovative new design of the shoulder pad. The shoulder pad ... comfort while controlling your pain while using cold therapy. By utilizing ice and water ...
(Date:10/12/2017)... Rockville, Maryland (PRWEB) , ... October 12, 2017 ... ... a magnetic drug delivery system that we intend to develop to enable prevention ... regimens can lead to severe hearing loss, especially in pediatric patients. For cisplatin, ...
Breaking Medicine News(10 mins):
(Date:10/10/2017)... , Oct. 10, 2017  NDS received FDA 510(k) clearance in ... medical-grade battery-powered display stand specifically designed for endoscopy environments. An innovative ... into a clinical solution to support the improvement of patient outcomes, ... Design ... Solution ...
(Date:10/7/2017)... 6, 2017   Provista, a proven leader ... billion in purchasing power, today announced a new resource ... The Newsroom is the online home for case ... expert bios, news releases, slideshows and events. ... wealth of resources at their fingertips, viewers can also ...
(Date:10/4/2017)... SEOUL, South Korea , Oct. 4, 2017 /PRNewswire/ ... launched its next-generation CPR training aide "cprCUBE" on Kickstarter. ... of chest compression during cardiac arrests with better efficiency ... patient-mannequins. It also offers real-time feedback on efficacy of ... The crowdfunding campaign has a goal to raise ...
Breaking Medicine Technology: